Research programme: anticancer therapeutics - Qrono
Alternative Names: QR 213Latest Information Update: 28 Sep 2021
Price :
$50 *
At a glance
- Originator Qrono
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Cancer in USA (Parenteral, Injection)
- 04 Aug 2017 Research programme: anticancer therapeutics- Qrono is available for licensing as of 04 Aug 2017. http://qrono.com/pipeline/ (Qrono pipeline, August 2017)
- 04 Aug 2017 Early research in Cancer in USA (Parenteral) (Qrono pipeline, August 2017)